-
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)
Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
Spike-Recovery-ELISA: Protokoll, Berechnung und Akzeptanzgrenzen(Post)Spike-Recovery-ELISA: Protokoll, Berechnung und Akzeptanzgrenzen Spike-Recovery prüft, ob Ihre Probenmatrix die ELISA-Messung verfälscht. Sie versetzen eine bekannte Menge Antigen in Ihre Probe und p
Pathological functions of IL-33/ST2 in IBD and Cancer(Post)By Charlotte O'Donnell PhD < As IL-33/ST2 is such a potent inducer of inflammation, it is not surprising that dysr
Targeting Immune Checkpoints as Cancer Therapy(Post)The advent of immune checkpoint targeting marks a significant milestone in the oncological field, offering a beacon of hope for patients battling cancer. This innovative approach leverages the bod
B-Cell Depletion: Why Anti-CD20 Spares the Antibody(Post)You can remove almost every B cell from an animal and barely move its antibody titre. That is not a failed experiment — it is the expected result, and it follows from one fact: CD20 is switched off a
Inflammation and the aging process(Post)by Ryan Wallis, PhD Aging and Disease Imagine a world where everything you do is missing just a little piece and as time goes on you start to lose sense entirely. This is the deva
ChIP Antibodies(Page)ChIP Antibodies | ChIP-Validated Histone & TF Antibodies | Assay Genie
4 étapes pour des comptes rendus ELISA défendables en laboratoire(Post)Un compte rendu ELISA exploitable réunit l’objectif de l’essai, la référence et le lot du kit, la méthode suivie, les densités optiques brutes, le modèle d’ajustement retenu (4PL ou 5PL) et les fa
샌드위치 엘리사(Page) Delete Every Microglial Cell, Then Ask What Changed(Post)Block one receptor and more than 90% of the microglia in a mouse brain are dead within a week. Not impaired — gone. Stop the block and they come back, repopulating from the survivors within another w
MHC Class I vs Class II: Key Differences & Functions [Guide](Post)Immunology Guide MHC Class I vs Class II: Key Differences & Functions [Guide] Major Histocompatibility Complex molecules present antigens to T
Treponema pallidum Antibodies: Comprehensive Guide to Diagnostic and Clinical Relevance(Post)Treponema pallidum, the causative agent of syphilis, triggers an immune response that produces antibodies detectable by laboratory tests. Diagnosing syphilis often involves detecting thes
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research(Post)Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
Mycoplasma Testing - Detection & Elimination(Page) Spotlight on Mitochondria(Post)Throughout my graduate and postgraduate studies I have been really intrigued and fascinated by the mitochondria, the organelle that keeps all of us running everyday! The more I learn about
COVID-19 Rapid POC CE-IVDテスト(25テスト)| Assay Genie(Post)COVID-19 Rapid POC CE-IVDテスト(25テスト) 概要説明 Getein COVID-19 Rapid POC(臨床現場即時)キットは新型コロナウィルス(
Ovarian Cancer: Symptoms, Causes, Diagnosis and Treatment(Post)Ovarian cancer is the fourth most common cancer in women. Ovarian cancer is when the normal cells in the ovary change and grow to form a tumour. Because the ovaries are located deep
CD47: Overcoming Tumor Evasion Through Macrophage Activation(Post)One of the greatest challenges in cancer therapy is how tumors evade immune detection. Among the mechanisms cancer cells exploit, the CD47 pathway has emerged as a major player in helping
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research(Post)Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
Tidutamab: Unlocking the Potential of SSTR2-Targeting in Oncology Research(Post)Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumor